Ratings
0
Nobody has rated this yet. Be the first!
Works
3
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
Factors affecting cytochrome P-450 3A activity in cancer patients.
